Jin and co-workers, who described the firstEZH2 degraders, claimed that solely inhibiting EZH2 without decreasingprotein level was insufficient to reduce breast cancer cell proliferation.Contrarily, the EZH2 degraders were able to completely suppress tumorgrowth in a triple-negative MDA-MB-468 breast cancer mouse model.94 The same approach was applied by AstraZenecaresearchers who reported the first proteolysis targeting chimeras(PROTACs) directed to EED that were capable of leading its degradation.90 This evidence concerns the gene EZH2 and breast carcinoma.